458 Brannan Street
138 articles with Invitae
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic cancer.
Invitae Corporation announced the pricing on September 5, 2019 of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Invitae Corporation (NYSE: NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Invitae Launches Detect Programs to Make it Easier for Patients to Get Genetic Testing for Prostate Cancer, Muscular Dystrophy and Heart Conditions
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment
Invitae Corporation, a leading medical genetics company, announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Invitae Corporation, a leading medical genetics company, has announced that it has entered into a definitive agreement to acquire Jungla Inc.
CORRECTING and REPLACING Civilization Ventures Announces Portfolio Exit with Acquisition of Singular Bio by Invitae (NYSE: NVTA)
Civilization Ventures is announcing its second portfolio exit in its third year of operations with the acquisition of Singular Bio, a private company developing novel technology for single molecule analysis of DNA, by Invitae, Inc., a publicly traded company at the forefront of the genomics revolution.
Invitae Reports Inducement Grants Under NYSE Rule 303A.08 to Former Employees of Singular Bio, Inc. in Connection with Closing of Acquisition
Invitae Corporation, a leading medical genetics company, announced that it granted time-based and development milestone-based restricted stock units to new employees who joined Invitae in connection with its acquisition of Singular Bio, Inc.
Civilization Ventures Announces Portfolio Exit with Acquisition of Singular Bio by Invitae (NASDAQ: NVTA)
Singular Bio, Inc. (“Singular Bio”) is a privately held company developing single molecule detection technology to enable lower costs and expanded use of high-quality, cell-free DNA analysis, initially for application in non-invasive prenatal screening
Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening
Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders
Genetic testing can identify causes of rare, progressive eye disorders
Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust
Invitae, a leader in medical genetics, announced the availability of its new service for consumers, which makes it easier for consumers to order and receive the same high-quality, medical genetic testing from Invitae that experts use and trust.
Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer Patients
Researchers from Invitae, a leading medical genetics company, will present data that underscore the clinical utility of comprehensive genetic information for patients with breast, colorectal, prostate and pancreatic cancer to inform treatment decisions.
New program improves access and speed to receiving a diagnosis for people and extended family members who may be living with Urea Cycle Disorders
Invitae Corporation announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock Conference on Wednesday, June 5, 2019 at 2:40 p.m. Central / 12:40 p.m. Pacific in Chicago.
Invitae Corporation announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2019 at 10:30 a.m. Eastern / 7:30 a.m. Pacific in New York City.
On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019
New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients
Results from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
Invitae Corporation announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Invitae Corporation announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City.